| ASSET | QUARTER | % RETURN |
|---|---|---|
Axsome Therapeutics (AXSM) | Q1 2020 | -43.81% |
Axsome Therapeutics (AXSM) | Q2 2020 | 45.73% |
Axsome Therapeutics (AXSM) | Q3 2020 | -13.48% |
Axsome Therapeutics (AXSM) | Q4 2020 | 13.71% |
Axsome Therapeutics (AXSM) | Q1 2021 | -30.37% |
Axsome Therapeutics (AXSM) | Q2 2021 | 17.67% |
Axsome Therapeutics (AXSM) | Q3 2021 | -50.66% |
Axsome Therapeutics (AXSM) | Q4 2021 | 14.14% |
Axsome Therapeutics (AXSM) | Q1 2022 | 9.12% |
Axsome Therapeutics (AXSM) | Q2 2022 | -8.42% |
Axsome Therapeutics (AXSM) | Q3 2022 | 17.17% |
Axsome Therapeutics (AXSM) | Q4 2022 | 69.33% |
Axsome Therapeutics (AXSM) | Q1 2023 | -20.62% |
Axsome Therapeutics (AXSM) | Q2 2023 | 16.41% |
Axsome Therapeutics (AXSM) | Q3 2023 | -2.74% |
Axsome Therapeutics (AXSM) | Q4 2023 | 13.7% |
Axsome Therapeutics (AXSM) | Q1 2024 | 1.53% |
Axsome Therapeutics (AXSM) | Q2 2024 | 0.88% |
Axsome Therapeutics (AXSM) | Q3 2024 | 12.28% |
Axsome Therapeutics (AXSM) | Q4 2024 | -6.21% |
Axsome Therapeutics (AXSM) | Q1 2025 | 36.81% |
Axsome Therapeutics (AXSM) | Q2 2025 | -5.93% |
